• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Bye-Bye China?

    Decentralized Trials Fuel AI Revolution in Clinical Research

    Self-Medication: Flexibility for Patients and Drug Manufacturers

    The Single-Use Mixing Landscape: Evaluating Your Options

    DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Novartis Invests in Credence MedSystems

    Ajinomoto Bio-Pharma Services and Humanigen Expand Manufacturing Agreement

    Almac Expands Global Biologics Testing Solutions

    GRAM Makes Major Investment in Additional Advanced Equipment

    Adare Pharma Solutions Opens New Small-Scale Lab
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Ajinomoto Bio-Pharma Services and Humanigen Expand Manufacturing Agreement

    GRAM Makes Major Investment in Additional Advanced Equipment

    Aphena’s $21M Cookeville Expansion Nears Completion

    PromoCell Receives EXCiPACT Certification

    Civica to Build an Essential Medicines Manufacturing Facility in Virginia
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Novartis Invests in Credence MedSystems

    Aphena’s $21M Cookeville Expansion Nears Completion

    Civica to Build an Essential Medicines Manufacturing Facility in Virginia

    WDSrx Expands Warehouse Network

    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Almac Expands Global Biologics Testing Solutions

    The State of Clinical Trial Technology

    Adare Pharma Solutions Opens New Small-Scale Lab

    The Future of Clinical Trials Series: Part II

    X-Chem Acquires IntelliSyn and AviSyn
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Syngene

    Cytovance Biologics

    Reed-Lane

    Alcami

    Almac Group
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    Cytovance Biologics

    Almac Group

    Reed-Lane

    Emergent BioSolutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    The Role of Electronic Monitoring in Maintaining Medication Adherence

    Digital solutions offer hope to get patients to take their medications properly.

    The Role of Electronic Monitoring in Maintaining Medication Adherence
    The Role of Electronic Monitoring in Maintaining Medication Adherence
    Table 1: Example of data produced by electronic monitoring of a subject´s medication intake for 363 days.
    Related CONTENT
    • 20th Annual Contracting & Outsourcing Conference & Exhibition
    • Pfizer, BioNTech Enter Vax Pact with COVAX
    • Aurigene Pharmaceutical Services ltd.
    • Ackley Machine Corporation
    • Lonza Capsules and Health Ingredients
    Bernard Vrijens, Scientific Lead, AARDEX Group10.14.20
    According to the World Health Organization, up to half of patients with chronic diseases fail to take their medications properly.1 Research shows many patients who are part of clinical trials do not maintain medication adherence either, despite being closely monitored.2

    Among many things, poor medication adherence is an on-going threat to drug development. Typically, by month 12, 40% of participants have stopped taking treatment against protocol specifications, and a further 15% implement poorly the study dosing regimen.2

    Historically, these protocol deviations have unfortunately gone frequently undetected by the more traditional non-digital measures of adherence, such as pill counts, blood sampling and patients’ self-reporting, as they inherently lack the precision to do so.

    One issue, numerous implications
    Medication adherence, which involves patients taking their medications in accordance with how they have been prescribed by their healthcare or medication provider, is a widespread challenge, which comes with wide-reaching implications for patients and health services worldwide. These include:
    • Severe health complications;
    • Premature deaths;
    • Increased healthcare services demand;
    • Wasted medications; and
    • Lower quality of life.
    It’s estimated that non-medication adherence contributes to almost 200,000 premature deaths Europe-wide each year. In the meantime, the annual cost of dealing with avoidable hospitalizations, emergency care and outpatient treatment reportedly currently stands at around €125 billion in Europe and $105 billion in the U.S.3

    Both patients and healthcare providers and other medical professionals can be negatively affected by medication non-adherence. For patients, their health can potentially be impacted by not taking the medication that has been prescribed to help with their health condition. While for healthcare providers working to establish the effectiveness of the medication being used, their efforts can become instantly compromised the moment medication non-adherence takes place.

    In drug development, key risks associated with patient non-adherence to study medications include underestimated drug efficacy to the point of trial failure, delayed approval of the investigational product, compromised patient safety, unduly large sample sizes and flawed regulators’ benefit-risk assessment at the time of the drug being registered.2

    Common causes of medication non-adherence
    Patient medication non-adherence is a global medical problem mainly due to the fact it is prevalent in so many medication-taking patients worldwide. And it’s a problem that can rapidly become increasingly complex due to the many different variables—for instance, the different patient views and attributes, illness characteristics and service issues—that are all at play at any given time.
    Some of the most common culprits that prevent medication adherence from taking place, include:
    1. Poor communication between the healthcare providers and patient.
    2. The patient having limited knowledge of the drug and how to use it.
    3. Fear of suffering adverse effects or side effects.
    4. The patient not being in agreement that they need the medication.
    5. Complicated medication routines.
    6. No perceived benefit from the medication.
    7. Forgetting to take the medication.
    It’s widely reported that lack of clear instruction from healthcare professional to patient, and the patient’s ability to understand the directions that they are asked to go away and follow, is one of the most common stumbling blocks to medication adherence.

    Studies have found that between 40 and 60% of patients could not correctly report what their physicians expected of them 10 to 80 minutes after they had been provided with the information. Furthermore, more than 60% of patients interviewed immediately after visiting their doctor had misunderstood the instructions they had been given in relation to taking their prescribed medication.

    Patient age has also been found to influence levels of medical adherence. For instance, medical intake among children is often impacted by the instructions and guidance that’s provided by an adult, i.e. their parent(s) or care provider. While industry research has reported that medication adherence among elderly patients stands at around less than 45%.

    Measuring medication adherence
    Given the widespread financial and practical implications of non-medication adherence, several measures have been developed and used over the years to help monitor and alleviate the issue.
    These measures include:
    • Direct methods—such as direct observed therapy, measuring the level of medication and blood or urine testing; and
    • Indirect methods—such as patient questionnaires and self-reporting, pill counts, rates of prescription refills, assessments of patients’ clinical responses, measuring physiologic markers and electronic medication monitors.
    The challenge with more tried-and-tested ways of monitoring
    Pill counts. In terms of the effectiveness of some of these methods, pill counts, which involve counting the number of tablets that are left in patients’ bottles or vials is simple. However, it can quickly become compromised if patients switch between medicine bottles or remove some tablets prior to their hospital visits to give the illusion of complying with their medication regime. Furthermore, it’s not possible to monitor medication dose timing, which is a crucial factor that can help determine clinical outcomes.

    Prescription refilling rate. Prescription refilling rate is a rough measure of adherence and is only available if it is carried out in accordance within a closed pharmacy system. This limitation is due to the fact that refills need to be counted several times. Furthermore, it does not provide the granularity of daily dosing which is crucial in understanding missed and overdose impacts. 

    Assessments of patients’ and clinical responses and measuring physiologic markers are too sparse to capture a behavior and thus of limited use in practice and research.

    Objective and precise monitoring
    Of all of the measures to have been implemented so far, electronic monitoring is widely recognized as enabling the most objective and precise form of medication adherence monitoring to be achieved.
    Generally speaking, the electronic compilation of dosing history data is enabled by smart packages, and is a highly effective way to passively monitor, identify, manage and document the risks associated with poor patient adherence to medications in clinical trials.

    This form of monitoring typically involves an electronic microcircuit being placed within the medication packaging, which automatically generates a timestamp each time the patient takes their medication.4 The timestamps are then stored within the packaging’s ‘memory’ and then wirelessly transferred to a central, cloud-based software system where it’s downloaded and analyzed.

    The captured data is used to provide a proxy for drug intakes. In turn, this enables the patients’ actual medication adherence to be mapped and graphs and charts and other forms of tangible analysis to be produced that illustrate a patient’s medication intake over a given period of time. An example of this this shown in Table 1, where a dot displays a dose taken and a vertical line represents a day of missed dosing.


    Table 1. Example of data produced by electronic monitoring of a subject's medication intake for 363 days.

    Detecting changes in medication intake behavior
    Aside from providing an overview of patients’ medication adherence, state of the art pioneering electronic monitoring systems, which incorporate online algorithms, provide the ability to drill down that bit further and truly understand patients’ medication-taking habits, as well as detect any potential issues.

    Segmenting and understanding different behaviors
    Assessing behavior changes provides homogeneous behavior periods that can then be characterized using a representative adherence measure. This way of working provides an appropriate summary of a patient’s adherence, which hasn’t been oversimplified by using a single adherence metric that’s computed on the whole monitoring period.

    As a consequence, using single metrics to understand patients’ medication intake can often confuse the analysis and interpretation of the results. This is due to the fact that:
    • The patients’ medication taking-behavior can change—it’s possible for it to get better or worse and continuously fluctuate over the period of time it is being monitored; and
    • Simple percentage statistics don’t distinguish between the different non-adherent behaviors that can range from perfect adherence, to drug holidays and regular drug omissions. All of these behaviors have the potential for the drug that’s been administered to lead to very different effects, depending on how it is, or isn’t, being used.
    Typical behavior changes include, drug holidays, weekend drop offs, different intake times, etc. It’s also possible to highlight several successive behavior changes, as well as patients whose behavior remained fairly consistent.

    Detecting medication adherence issues early on
    Monitoring patients’ medication adherence also provides an invaluable opportunity to identify any key behavior changes the moment they happen. This is essential in detecting any issues that may require healthcare or professional medical support early on.

    For example, you could take the data from patients whose medication adherence for a daily anti-cancer drug is being monitored between six and 421 days. The algorithm is then able to detect the behavior changes during the monitoring period triggering a healthcare provider support focus discussion with the patient. 

    For instance, because the algorithm is online, it can be applied during on-going patient monitoring and send an alert to their subject’s healthcare provider or study coordinator the moment a behavior change has been detected.

    This trigger then enables the healthcare provider to reach out to the patient to understand what has caused the behavior change (e.g. if they’ve been experiencing side effects). If the new behavior has a worse adherence than the previous one, then the healthcare provider can advise the patient to switch back to their previous medication intake habit, as well as provide them with the guidance and instructions that will enable them to do so effectively.

    The benefits of electronic monitoring within  the pharma industry
    Medication adherence management methods have the ability to single-handedly improve clinical results and conclusions. However, electronic monitoring technology further enables:
    • Drug developers or clinical study supervisors to achieve true optimization for their drug development, using proven and effective monitoring of patient non-compliance within their clinical trials; and
    • Brand managers or innovation packaging managers to help their organization stand out and differentiate themselves against their competitors by taking the additional steps to improve the safety and efficacy of their therapies
    The ability to measure patient signals and automatically or promptly administer, medication provides a closed feedback loop that has the potential to optimize effectiveness for individual patients, ensure the robust continuation of medication and optimize patients’ outcomes.

    Non-electronic methods, such as pill counts, blood sampling and patients’ self-report, may be widely used, but they are not accurate, tend to overestimate medication intake, and can bias the results of adherence research.

    Overall, electronic monitoring is at the cornerstone of new technology adoption to replace unreliable methods to assess medication adherence. This is especially true given that today’s industry-leading platforms have the ability to:
    • Optimize drug development using adherence-informed clinical trials;
    • Ensure high fidelity to the dosing regimen specified in the clinical trial protocols, as suggested; by the U.S. FDA and EMA
    • Identify structural deficiencies during clinical trials;
    • Gather key patient adherence behavioural data for successful marketing strategy;
    • Improve medication adherence, data quality, and integrity; and
    • Support proactive evidence-based risk mitigation strategies.
    Smart package monitoring = 97% accuracy
    Advanced digital medication adherence monitoring provides complete oversight of the adherence metrics and risk indicators that matter the most. According to studies, smart electronic packaging/device monitoring is 97% accurate, ahead of drug levels and markers (70%), pill counts (60%), healthcare professional ratings (50%) and patient self-reporting and electronic patient diaries (27%).
    Smart packaging is friction-less and thus more effective compared to using just app-based methods. App-based solutions may struggle to gain compliance from non-adherent types compared to if you were using passive measurements from smart packaging, which will capture both adherent and non-adherent types of patients.

    Digital times call for digital measures
    Particularly state-of-the-art measures that have been designed to deliver clinical trial success by using reliable, up-to-the minute, evidence-based tactics. These measures have been honed and perfected over several product generations.

    Such digital solutions not only provide more reliable data, but also more detailed data about actual patient adherence, such as dose frequency, dose interval and medication dose timing—details that traditional methods do not capture. Electronic monitoring shows that poor adherence, especially dosage omission or changing intervals, is more prevalent than previously recognized.

    These smarter monitoring systems enable sponsors to improve drug efficacy by managing patient adherence to the study medications. With digital medication adherence monitoring, pharmaceutical companies can safeguard their clinical trials and build a stronger argument about the efficacy of their medication from the development stage to commercialization. 

    References
    1. https://www.who.int/chp/knowledge/publications/adherence_report/en/
    2. Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Blaschke TF, Osterberg L, Vrijens B, Urquhart J. Annu Rev Pharmacol Toxicol. 2012;52:275-301
    3. https://www.oecd-ilibrary.org/social-issues-migration-health/investing-in-medication-adherence-improves-health-outcomes-and-health-system-efficiency_8178962c-en
    4. https://www.oecd-ilibrary.org/social-issues-migration-health/investing-in-medication-adherence-improves-health-outcomes-and-health-system-efficiency_8178962c-en


    Bernard Vrijens, PhD, is Scientific Lead at AARDEX Group and an Invited Professor of Biostatistics at Liège University in Belgium. He currently leads a research program investigating (a) the most common errors in dosing using a simple but robust taxonomy, (b) particular dosing errors that can jeopardize the efficacy of a drug, and (c) the optimal measurement-guided medication management program that can enhance adherence to medications and maintain long-term persistence. Dr. Vrijens is also the co-author of seven book chapters, over 100 peer-reviewed scientific papers, and named as inventor on 6 patents. He is a founding member of the International Society for Medication Adherence (ESPACOMP), and an active member of several EU- and US-funded collaborative projects around the theme of adherence to medications.
    Related Searches
    • Information Technology
    • Clinical Trials
    Suggested For You
    20th Annual Contracting & Outsourcing Conference & Exhibition 20th Annual Contracting & Outsourcing Conference & Exhibition
    Pfizer, BioNTech Enter Vax Pact with COVAX  Pfizer, BioNTech Enter Vax Pact with COVAX
    Aurigene Pharmaceutical Services ltd. Aurigene Pharmaceutical Services ltd.
    Ackley Machine Corporation Ackley Machine Corporation
    Lonza Capsules and Health Ingredients Lonza Capsules and Health Ingredients
    PCI Pharma Services PCI Pharma Services
    Catalent Pharma Solutions Catalent Pharma Solutions
    MedPharm MedPharm
    PharmaServe PharmaServe
    Regis Custom Pharma Regis Custom Pharma
    Intini Marketing Intini Marketing
    ViscoTec America ViscoTec America
    Momentive, Stevanato Partner to Offer Vial Packaging Solution   Momentive, Stevanato Partner to Offer Vial Packaging Solution
    CellGenix Expands Facility CellGenix Expands Facility
    Greenwich Lifesciences Completes Manufacturing of GP2 Greenwich Lifesciences Completes Manufacturing of GP2

    Related Features

    • Clinical Trials | Information Technology | R&D
      Decentralized Trials Fuel AI Revolution in Clinical Research

      Decentralized Trials Fuel AI Revolution in Clinical Research

      The life sciences industry is giving clinical a full makeover, dramatically improving how new therapeutics are developed.
      Nick Moss, Vice President of Analytics and Machine Learning, Medable 11.17.20

    • Information Technology
      You Need Solutions, Digitization is the Answer

      You Need Solutions, Digitization is the Answer

      Cloud technology helps today’s contract manufacturers be agile, transparent and efficient.
      Brian Curran, Senior Vice President of Strategic Growth, MasterControl 10.14.20

    • Information Technology
      Five Ways to Enhance Clinical Operational Efficiencies Utilizing AI

      Five Ways to Enhance Clinical Operational Efficiencies Utilizing AI

      The proven promise and huge potential of using AI and ML to accelerate drug discovery.
      Lucas Glass, Gary Shorter, and Rajneesh Patil, IQVIA 11.20.19


    • Clinical Trials
      Gene Therapy Trials

      Gene Therapy Trials

      Applications and the limitations of real-world data.
      Karen Ooms, Executive Vice President and Head of Statistics, Quanticate 09.16.19

    • Information Technology
      A Brave New World of Data Integrity

      A Brave New World of Data Integrity

      How modern CMOs are keeping up with stringent regulatory guidelines by embracing advanced laboratory information systems.
      Bob Voelkner, VP Sales and Marketing, LabVantage 06.13.19

    • Clinical Trials | Information Technology
      The New Horizon: Metaprise Analytics in Life Sciences

      The New Horizon: Metaprise Analytics in Life Sciences

      Going beyond enterprise analytics to metaprise analytics—patient-centric systems that create a data driven trial team.
      Michelle Longmire, MD, CEO and Founder, Medable 05.07.19


    • Information Technology
      The Manufacturing Revolution In Medicine

      The Manufacturing Revolution In Medicine

      Real-time data insights help both pharma companies and contract manufacturers meet regulatory requirements while ensuring high production standards.
      Petter Moree, OSIsoft, LLC 05.07.19

    • Clinical Trials
      Clinical Trial Feasibility

      Clinical Trial Feasibility

      How to reduce late-stage trial risk with feasibility analysis
      Alan Scott and Denis McMillan, PAREXEL International 04.05.19

    • Clinical Trial Materials | Clinical Trials | Supply Chain
      Optimizing Clinical Supply Management

      Optimizing Clinical Supply Management

      IRT system design strategies to help life science companies cut drug wastage across clinical programs.
      Bart Nicholson, Director of Customer Success for IRT, CRF Bracket 04.05.19


    • Information Technology
      Industry 4.0 in the Pharma Industry

      Industry 4.0 in the Pharma Industry

      Digitization is not a single-handed project.
      Dr. Christian Hanisch, Project Manager Industry 4.0 Pharma, Bosch Packaging Technology 03.06.19

    • Information Technology
      Digitization: Pharma 4.0

      Digitization: Pharma 4.0

      A look at how technology is impacting the pharma industry
      Fatih Kaya and Gerald Buerkle, Vetter Pharma 01.25.19

    • Information Technology
      FDA & Data Integrity

      FDA & Data Integrity

      FDA Publishes Final Guidance on Data Integrity
      Robert Marohn, Director of Quality Business Systems, Kite Pharmaceutical 01.25.19


    • Information Technology | Serialization | Supply Chain
      Serialization Compliance

      Serialization Compliance

      Automated data controls during packaging help improve compliance.
      Miguel Pitarch, Executive Director, Global Serialization, Bristol-Myers Squibb & the Bristol-Myers Squibb Serialization Team 11.13.18

    • Clinical Trial Materials | Information Technology
      Interactive Response Technology in Clinical Trial Supply

      Interactive Response Technology in Clinical Trial Supply

      Exploring the benefits of including IRT professionals earlier in trial planning
      Dave Holly, Senior Manager, IRT Development and Operations, Sharp Clinical Services 10.10.18

    • Clinical Trials | R&D
      Improving Pharma R&D Efficiency: The need to transform clinical trials

      Improving Pharma R&D Efficiency: The need to transform clinical trials

      Cost pressures on drug development are driving the search for savings and efficiencies—but efforts need to be integrated if t
      ICON plc 10.10.18

    Trending
    • Integrated Continuous Manufacturing ICM
    • Humanigen, Emergent Enter Covid-19 Partnership
    • 500+ Sites Join Inato’s Industry Marketplace
    • Samsung Bioepis Opens New Headquarters
    • CDMO Northway Biotech Expands In U.S.
    Breaking News
    • Novartis Invests in Credence MedSystems
    • Ajinomoto Bio-Pharma, Humanigen Expand Manufacturing Agreement
    • Almac Expands Global Biologics Testing Solutions
    • GRAM Makes Major Investment in Additional Advanced Equipment
    • Adare Pharma Solutions Opens New Small-Scale Lab
    View Breaking News >
    CURRENT ISSUE

    January/February 2021

      View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Omega-3s Evidenced to Reduce Low-Grade Inflammation in Elderly Men
    MIND and Mediterranean Diets Linked to Later Onset of Parkinson’s Disease
    Kerry Launches Web-Based Tool for Plant-Based Formulation Challenges
    Coatings World

    Latest Breaking News From Coatings World

    Keyland Polymer UV Powder, LLC Launches UVMax Defender
    Scott McLaughlin to Race in PPG Colors During Rookie INDYCAR Season
    Vink Chemicals Offers parmetol PSG
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Butterfly Network Appoints New Leader
    BD Names Chairman of Board
    Interplex Acquires OCP Group
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Novartis Invests in Credence MedSystems
    Ajinomoto Bio-Pharma, Humanigen Expand Manufacturing Agreement
    Almac Expands Global Biologics Testing Solutions
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Bésame Cosmetics Collaborates with Disney on Mary Poppins Collection
    The Estée Lauder Companies Announces Game-Changing Sustainability Goals for Travel Retail
    Aura Introduces Customizable Hair Care
    Happi

    Latest Breaking News From Happi

    RB Partners with Airbnb
    L'Occitane US Files for Bankruptcy
    Nice-Pak Receives EPA Approval for Disinfectant Wipes
    Ink World

    Latest Breaking News From Ink World

    Epson Partner Creates Label Applicators for Pharmaceutical Products
    Smurfit Kappa Sets New Sustainability Targets with Better Planet 2050
    Paragon Expands Direct Mail Capabilities with Ricoh Pro VC70000
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Great Lakes Label debuts new website
    Epson partner creates label applicators for pharmaceutical products
    ACTEGA removes chemicals from laminating adhesives
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    American Made Production Equipment for Mask Manufacturers
    Kimberly-Clark Releases Q4, Full Year Results
    Freudenberg to Establish Apparel Interlining Competence Centers
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    FDA Green Lights Inspired Spine's Trident SI Joint Screw System
    Spinal Elements' Lucent XP-Curved Expandable TLIF Gains FDA Nod
    FDA OKs OrthoSpin's 2nd Gen Robotic, Digital External Fixation System
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    North American Semiconductor Equipment Industry Posts December 2020 Billings
    First Solar Signs Definitive Agreement to Sell US Development Platform to Leeward
    PRINTING United Alliance Announces TAGA Presents Virtual Event

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login